A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseThe cochrane library is changingA review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisionsNet clinical benefit of oral anticoagulants: a multiple criteria decision analysisComputing limits on medicine risks based on collections of individual case reportsEthics and epistemology of accurate prediction in clinical research.Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohortsIntegration of PKPD relationships into benefit-risk analysisAnalysis of safety data in clinical trials using a recurrent event approach.A comparison of analytic hierarchy process and conjoint analysis methods in assessing treatment alternatives for stroke rehabilitation.Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials.A framework for organizing and selecting quantitative approaches for benefit-harm assessment.Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatmentMulticriteria decision analysis in oncology.Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidenceRanking adverse drug reactions with crowdsourcing.Use of the analytic hierarchy process for medication decision-making in type 2 diabetesQuantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPDQuantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial.Benefit-risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experimentAssessment of the therapeutic value of new medicines marketed in AustraliaAcute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims.Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature.Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment.Use of number needed to treat in cost-effectiveness analyses.The risks of risk aversion in drug regulation.Considerations for the clinical use of contrast agents for cellular MRI in regenerative medicine.Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature.Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation.Should benefit-risk assessment have its own drug "label"?Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines.Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment.
P2860
Q24234399-880826B8-7B1D-4CBF-AF14-5B23762201B1Q24236495-03D4E3B4-5170-478B-8534-DF7A31ED5F94Q28084751-A65B917A-F4F2-4F06-B411-0C081CA290D0Q28546594-FAD7444F-F143-4CC1-8B09-23EE6D9636F5Q28652138-A3E4A0A2-5A0E-46D1-AA55-2D6D3CD9A39DQ30367094-E92723DA-8B89-40C7-92E7-72EFA6830E4DQ30581769-4705AA3E-F679-4C98-AC75-268568AC3CDCQ30671571-5FE57128-1CE8-4ADE-88DB-A8670C92FD3FQ30755604-B5F5F059-B9F9-44D4-B39D-1D69035AA80AQ34241819-4E045034-2718-4E0A-A90C-E8F00F67ED29Q34259078-65D7C85D-FDF9-4941-8FEE-105C735BEA1AQ34481196-684A9563-42B3-4569-B04E-B039B379BF70Q34542774-311209B9-B59C-466E-9D37-E995355BC779Q35030155-5C524904-16ED-4351-9963-CEEF471BCE76Q35054713-AC40B247-A297-4DB5-BC98-6C137611E685Q35237330-3AF51F1C-2CD8-43E4-AF8F-6E7499FC82EFQ35289332-40140456-6D3A-4DD7-A8B2-8A3FB9374B7DQ35639204-CEFFDC68-C9F4-4C66-884C-EF16133E2FF0Q35681671-9EF47470-E9BD-4B1D-B86E-F5DDA7D95398Q35811145-DC5764A0-F8A1-4D5A-9DC4-9A75F16D4458Q36526904-6694D2FB-C504-4A36-8F71-6F8853EA879AQ36625421-FD28482B-6BA1-4793-80E5-87105D1BE218Q37703341-63181F13-F1EE-4543-891A-C656A9D67AACQ37724114-5482C7BB-43A5-4825-9A3D-BB17406A8874Q37742842-594C5DBC-029B-4BEB-9DD1-468253A529C8Q37945540-15D8100D-430A-4C4E-B8CA-EE37788C5168Q37952076-AF32DF5A-AC61-418D-B956-A801F36D998FQ38086820-DE9BB125-F8DD-44C2-945C-841A7E9D7979Q38162718-52FBA9E4-B675-472F-AFC3-529203E0FB33Q38174553-C3910E32-2789-4288-8CC9-C1079A175602Q38185989-551B78D7-68DC-4A91-8D9B-E0BAA4F746A0Q38211405-37EBF535-97E0-4F74-A18A-C85B2C0026FEQ38217011-B663F5A1-0611-4E97-BC09-E710B19730E5Q38271655-2D72AEF0-A7A6-4816-87BF-E16B7DD6DD1BQ38485343-C08057C3-CE22-4E31-8412-661F62594C60Q38564142-826DFC2C-AC69-4329-925C-C81CD05E3359Q38583668-2FC2EE1B-F1C3-4090-BB91-D1EF9DE3BA00Q38587979-71A0ED6B-12F2-43C2-A2CC-DAE20FD6A21CQ38607318-4F1D3354-9DB3-4AFB-935E-EAD9D7ABFAAEQ38684565-0C10ABBA-5E06-47BF-892E-64F3985EDC6A
P2860
A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A review of quantitative risk- ...... efit management working group.
@en
A review of quantitative risk- ...... efit management working group.
@nl
type
label
A review of quantitative risk- ...... efit management working group.
@en
A review of quantitative risk- ...... efit management working group.
@nl
prefLabel
A review of quantitative risk- ...... efit management working group.
@en
A review of quantitative risk- ...... efit management working group.
@nl
P2093
P1433
P1476
A review of quantitative risk- ...... efit management working group.
@en
P2093
Boyang Bian
Dennis W Raisch
Jeff J Guo
John Doyle
Swapnil Pandey
Yvonne Lis
P304
P356
10.1111/J.1524-4733.2010.00725.X
P577
2010-04-15T00:00:00Z